C12N 2750/14341
Use of virus, viral particle or viral elements as a vector
C12N2750/14341 (Use of virus, viral particle or viral elements as a vector) appears on 34 US grants and 60 published applications in this corpus.
Search patents in C12N- Granted patents
- 34
- Published applications
- 60
- Assignees
- 47
- Inventors
- 131
- Latest grant
- 29 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 4 |
| 2014 | 1 | 3 |
| 2015 | 3 | 3 |
| 2016 | 0 | 2 |
| 2017 | 5 | 2 |
| 2018 | 2 | 3 |
| 2019 | 2 | 5 |
| 2020 | 2 | 4 |
| 2021 | 2 | 3 |
| 2022 | 3 | 7 |
| 2023 | 0 | 9 |
| 2024 | 2 | 8 |
| 2025 | 2 | 2 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2750/14343Viral genome or elements thereof as genetic vectorIndexing code32
- C12N 2750/14345Special targeting system for viral vectorsIndexing code4
- C12N 2750/14344Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code3
- C12N 2750/14342Virus or viral particle as vehicleIndexing code0
Recent patents
- Canine parvovirus (CPV) nanobody CPV-VHH-H1 and use thereof29 Jul 2025US 12,371,476 B2Institute of Animal Sciences of Caas
- Nucleic acid molecules and uses thereof for non-viral gene therapy22 Jul 2025US 12,364,774 B2Bioverativ Therapeutics Inc.
- cis and trans requirements for terminal resolution of human bocavirus 124 Dec 2024US 12,173,305 B2University of Iowa Research Foundation
- Bocaparvovirus small noncoding RNA and uses thereof4 Jun 2024US 11,999,965 B2University of Iowa Research Foundation
- Vectors for liver-directed gene therapy of hemophilia and methods and use thereof23 Aug 2022US 11,419,950 B2Vrije Universiteit Brussel
- Cis and trans requirements for terminal resolution of human bocavirus 130 Apr 2026US 2026/0117253 A1University of Iowa Resarch Foundation
- Rna and dna base editing via engineered adar recruitment2 Apr 2026US 2026/0092292 A1The Regents of the University of California
- Nucleic acid molecules and uses thereof for non-viral gene therapy28 Aug 2025US 2025/0269067 A1Bioverativ Therapeutics Inc.
- Adeno-associated virus compositions having increased heart enrichment12 Jun 2025US 2025/0188128 A1Capsida, Inc.
- Bocaparvovirus small noncoding rna and uses thereof21 Nov 2024US 2024/0384294 A1University of Iowa Research Foundation
Most cited
By later US patents
- Parvovirus protein presenting capsids66US 5,916,563 AUnited States of America · 1999
- Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof40US 9,598,468 B2University of Florida Research Foundation, Inc. · 2017
- Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell23US 6,281,009 B1The General Hospital Corporation · 2001
- Retinal OFF circuit-specific promoter21US 9,579,399 B2Friedrich Miescher Institute for Biomedical Research · 2017
- B19 parvovirus capsids17US 5,508,186 AThe United States of America as represented by the Secretary of Health and Human Services · 1996